Merrion Pharmaceuticals has announced that it has postponed its plan to list on New York's NASDAQ index.
The specialty pharmaceuticals company said in a statement that the decision was taken 'in the light of ongoing difficult market conditions'.
Merrion began unconditional trading on Dublin's IEX market on December 18.
Shares in the firm, which develops improved oral dosage forms of drugs, closed with no change at €4.40 this evening.
